Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Authors:
Open Access
- 23 May 2020
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (12) , 2286-2293
Abstract
Acute graft-versus-host disease (aGVHD) is a serious complication after stem cell transplantation and is associated with high non-relapse mortality. If steroid treatment as first-line therapeutic approach fails, treatment options are limited. In retrospective studies, ruxolitinib, a selective Janus kinase 1/2 inhibitor as well as extracorporeal photopheresis (ECP) could show high efficacy in treatment of steroid refractory acute and chronic GVHD. Here, we report single-center experience of combining JAK-inhibitor treatment with ECP in 18 patients with severe steroid refractory aGVHD of lower GI-tract. The treatment was well tolerated and no severe cytopenia (grade IV) occurred, in three patients grade III cytopenia could be observed. Response was complete or partial in 44% and 11%, respectively, resulting in an estimated 2 year overall survival of 56%. Steroids were tapered rapidly with a median time of 2 days for halving of dosage avoiding additional steroid-associated side effects. Under treatment with ruxolitinib and ECP, an increased level of regulatory T cells could be observed elucidating direct effects of this treatment on immune response.Keywords
This publication has 18 references indexed in Scilit:
- Classification systems for chronic graft-versus-host diseaseBlood, 2017
- Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT EffectsClinical Cancer Research, 2015
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyLeukemia, 2015
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseBlood, 2014
- Graft-versus-host diseaseCurrent Opinion in Hematology, 2014
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host DiseaseNew England Journal of Medicine, 2011
- Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantationLeukemia Research, 2010
- How I treat refractory acute GVHDBlood, 2007
- 1994 Consensus Conference on Acute GVHD Grading.1995